What is Ligandal?
Ligandal operates at the forefront of biotechnology, specializing in advanced targeting technology designed to accelerate precision medicine. The company's innovative platform focuses on delivering therapeutics directly to the exact molecular sites of disease, aiming to shift treatment paradigms from symptom management to addressing the root causes of ailments with atomic accuracy. Central to its approach is the proprietary Peptide Direct Conjugate (PDC) technology, which unlocks the potential for targeted medicine delivery, enabling the pursuit of cures for conditions previously considered intractable. Ligandal's strategic objective is to empower researchers and pharmaceutical companies to target diseases at their molecular origins, thereby enhancing patient outcomes through highly precise and personalized therapeutic solutions.
How much funding has Ligandal raised?
Ligandal has raised a total of $84K across 1 funding round:
Debt
$84K
Debt (2021): $84K with participation from PPP
Key Investors in Ligandal
PPP
Public-Private Partnership
What's next for Ligandal?
With significant Series B/C stage funding and substantial expansion capital, Ligandal is poised for accelerated growth and development. The company's focus on its PDC technology suggests a strategic emphasis on scaling manufacturing capabilities, expanding clinical trial pipelines, and potentially forging new partnerships within the precision medicine ecosystem. This infusion of capital will likely fuel further research and development, aiming to translate its innovative targeting platform into a broader range of therapeutic applications and solidify its market position in the competitive biotechnology landscape.
See full Ligandal company page
